Biodexa Pharmaceuticals Plc (BDRX) stock
BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.14−0.10 (-4.46%)
Close on Nov 17, 2026Market cap $4.83MP/E –Yield –
Biodexa Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -£8.65M. The highest annual figure on record is -£7.00M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -£8.65M | – |
| FY2024 | Dec 31, 2024 | -£9.20M | – |
| FY2023 | Dec 31, 2023 | -£8.01M | – |
| FY2022 | Dec 31, 2022 | -£8.93M | – |
| FY2021 | Dec 31, 2021 | -£7.00M | – |
| FY2020 | Dec 31, 2020 | -£23.04M | – |
| FY2019 | Dec 31, 2019 | -£11.32M | – |
| FY2018 | Dec 31, 2018 | -£11.82M | – |
| FY2017 | Dec 31, 2017 | -£13.28M | – |
| FY2016 | Dec 31, 2016 | -£9.65M | – |
| FY2015 | Dec 31, 2015 | -£12.92M | – |
See a number that looks wrong?